Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.42 |
| ▸ | LDHB | P07195 | 1/20 | 0.42 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | FNTA | P49354 | 1/20 | 0.32 |
| ▸ | FNTB | P49356 | 1/20 | 0.32 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404916 | 1.00 | LDHA (0.42) | LDHALDHBGRIK1FFAR3GRIA4 | |
| SCHEMBL1831176 | 0.88 | TDP1 (0.41) | LDHALDHBGRIK1FFAR3GRIA4 | |
| SCHEMBL1831174 | 0.88 | TDP1 (0.41) | LDHALDHBGRIK1FFAR3GRIA4 | |
| SCHEMBL8688580 | 0.88 | TDP1 (0.41) | LDHALDHBGRIK1FFAR3GRIA4 | |
| SCHEMBL101165 | 0.85 | FFAR3 (0.53) | GRIK1FFAR3GRIA4GRIK3GRIK5 | |
| SCHEMBL42601 | 0.85 | FFAR3 (0.53) | GRIK1FFAR3GRIA4GRIK3GRIK5 | |
| SCHEMBL42603 | 0.85 | FFAR3 (0.53) | GRIK1FFAR3GRIA4GRIK3GRIK5 | |
| Hydrochloric Acid SCHEMBL9622192 | 0.82 | FFAR3 (0.50) | GRIK1FFAR3GRIA4GRIK3GRIK5 | |
| SCHEMBL305428 | 0.82 | FFAR3 (0.50) | GRIK1FFAR3GRIA4GRIK3GRIK5 | |
| SCHEMBL304063 | 0.82 | FFAR3 (0.50) | GRIK1FFAR3GRIA4GRIK3GRIK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208314-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2007-04-24 | — | — | US | disclosed |
| US-7138382-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2006-11-21 | — | — | US | disclosed |
| US-7098032-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS BIO CORPORATION (US) | 2006-08-29 | — | — | US | disclosed |
| EP-1102785-A4 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | MIRUS CORP (US) | 2006-04-05 | — | — | EP | disclosed |
| US-6919091-B2 | Compositions and methods for drug delivery using pH sensitive molecules | MIRUS CORPORATION (US) | 2005-07-19 | — | — | US | disclosed |
| US-20050123600-A1 | Compositions and methods for drug delivery using pH sensitive molecules | ROCHE MADISON INC. | 2005-06-09 | — | — | US | disclosed |
| US-20040058446-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Madison Inc. | 2004-03-25 | — | — | US | disclosed |
| US-20030199090-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Pharmaceuticals, Inc. | 2003-10-23 | — | — | US | disclosed |
| US-6630351-B1 | Transfecting a cell by attaching a reversible labile membrane activity inhibitor to a melittin peptide; adding peptide to solution containing the nucleic acid; endocytosis | MIRUS CORPORATION | 2003-10-07 | — | — | US | disclosed |
| US-20030026841-A1 | Compositions and methods for drug delivery using pH sensitive molecules | Arrowhead Madison Inc. | 2003-02-06 | — | — | US | disclosed |
| EP-1102785-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | Mirus Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000075164-A1 | COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES | MIRUS CORPORATION (US) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058446-A1 | Compositions and methods for drug delivery using pH sensitive molecules | ABCC1, DNA2, ANXA6 | LDHA 34/4885LDHB 50/4885GRIK1 3245/4885 |
| US-20030026841-A1 | Compositions and methods for drug delivery using pH sensitive molecules | POLI, POLN, POLRMT | LDHA 1265/4885LDHB 1438/4885GRIK1 3141/4885 |
| US-20050123600-A1 | Compositions and methods for drug delivery using pH sensitive molecules | POLI, POLN, POLRMT | LDHA 1265/4885LDHB 1438/4885GRIK1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.